Tirzepatide has large randomized human trials and approved medicines for specific indications. Evidence is strong for those studied uses, but results and approvals still depend on the population, product, formulation, indication and country.
Still uncertain: Safety/quality of unverified products and uses outside authorised indications are not established.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
STUDY DATA VISUAL
SURMOUNT-1 study snapshot: mean body-weight change
Adults with obesity/overweight without diabetes · N=2,539 · 72 weeks · treatment-regimen estimand in the intention-to-treat population · mean percentage body-weight change from baseline
Trial averages are population-level results, not personal predictions. The approved product, indication and prescribing information remain separate questions. Bars use a common 0–25% weight-change scale across these WhichPeps charts. Separate trials are not head-to-head comparisons; populations, estimands and designs can differ.
View chart values as text
SURMOUNT-1 study snapshot: mean body-weight change table
Group
Mean body-weight change
Placebo
−3.1%
5 mg
−15.0%
10 mg
−19.5%
15 mg
−20.9%
SURMOUNT-1 study snapshot: mean body-weight change table
What is it?
GIP/GLP-1 receptor agonist peptide
Entity type
Peptide
Research focus
Type 2 diabetes, obesity, weight management
Human evidence
Large Phase III obesity evidence shows substantial weight loss. SURMOUNT-OSA demonstrated reductions in sleep-apnoea severity, and SURMOUNT-MAINTAIN showed better maintenance of prior weight reduction with continued tirzepatide than switching to placebo.
Regulatory status
Tirzepatide is authorised in licensed products such as Mounjaro for type 2 diabetes and adult weight management in the EU; authorization is product- and jurisdiction-specific.
Main limitations
Safety/quality of unverified products and uses outside authorised indications are not established.
Safety
GI adverse effects are common; hypoglycaemia risk rises with some diabetes drugs; product labels contain additional warnings.
Evidence reviewed
2026-09-20
i
Large Phase III obesity evidence shows substantial weight loss. SURMOUNT-OSA additionally demonstrated large reductions in sleep-apnea severity in adults with obesity and moderate-to-severe OSA.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Weight loss in adults with obesity/overweight without diabetes
Human evidence
Strong Phase III human evidence
Context: SURMOUNT-1 population
Finding: Substantial and sustained weight reduction was demonstrated in a large controlled trial.
Safety / tolerability context: GI adverse effects and treatment discontinuation occurred; results do not imply equivalent safety/quality of non-authorized products.
2024 · Two randomized double-blind placebo-controlled trials · n=469
AHI treatment differences versus placebo were about -20.0 events/hour in trial 1 and -23.8 events/hour in trial 2; secondary sleep/cardiometabolic measures also improved.
SURMOUNT-MAINTAIN: Tirzepatide for maintenance of body-weight reduction in adults with obesity
2026 · Randomized, double-blind, placebo-controlled Phase 3b trial after open-label weight reduction · n=441 enrolled; 378 randomized at week 60
Estimated body-weight change from baseline to week 112 was -21.9% with continued maximum tolerated dose, -16.6% after reduction to 5 mg, and -9.9% after switching to placebo.
GI adverse effects are common; hypoglycaemia risk rises with some diabetes drugs; product labels contain additional warnings.
Gastrointestinal adverse effects are common; labelled warnings/contraindications, titration and approved formulation matter.
Technical details
Mechanism / biologyDual agonism at GIP and GLP-1 receptors improves glucose-dependent insulin signalling and reduces food intake.
Route / formulation boundaryUnverified research-market material or non-authorised pens are not equivalent to licensed tirzepatide medicines merely because the active-ingredient name matches.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. UK licensed dosing example. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
3structured study records
2outcome records
8linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
